ReviewCurrent gastroenterology reports2012
Iron metabolism in Nonalcoholic Fatty Liver Disease.
Review in Current gastroenterology reports, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed, 2 syntheses or guidelines pooled it, 117 citations in OpenAlex.
- Association of serum ferritin with non-alcoholic fatty liver disease: a meta-analysis.Lipids in health and disease · 2017Pooled it
- Genetic factors that affect nonalcoholic fatty liver disease: A systematic clinical review.World journal of gastroenterology · 2016Pooled it
- Association between pattern of hepatic iron deposition and severity of MASH among patients enrolled in the NASH Clinical Research Network.Hepatology communications · 2025Article
- Toxins to treatments: Impact of environmental pollutants, gut microbiota, and natural compounds on non-alcoholic fatty liver disease progression.World journal of hepatology · 2025Review
- Hepatic ferredoxin reductase modulates mitochondrial function and iron homeostasis in metabolic dysfunction-associated steatotic liver disease.Research square · 2025Article
- Iron overload is closely associated with metabolic dysfunction-associated fatty liver disease in type 2 diabetes.Obesity (Silver Spring, Md.) · 2025Article
- Influence of Gadoxetate disodium to the hepatic proton density fat fraction quantified with the Dixon sequences in a rabbit model.Abdominal radiology (New York) · 2024Article
- Article
- Supplementation of Micro- and Macronutrients-A Role of Nutritional Status in Non-Alcoholic Fatty Liver Disease.International journal of molecular sciences · 2024Review
- Iron, Oxidative Stress, and Metabolic Dysfunction-Associated Steatotic Liver Disease.Antioxidants (Basel, Switzerland) · 2024Review
- Contributing roles of mitochondrial dysfunction and hepatocyte apoptosis in liver diseases through oxidative stress, post-translational modifications, inflammation, and intestinal barrier dysfunction.Cellular and molecular life sciences : CMLS · 2024Review
- Quantitative MRI of diffuse liver diseases: techniques and tissue-mimicking phantoms.Magma (New York, N.Y.) · 2023Review
- Vitamin E Induces Liver Iron Depletion and Alters Iron Regulation in Mice.The Journal of nutrition · 2023Article
- Iron as a therapeutic target in chronic liver disease.World journal of gastroenterology · 2023Review
- Iron-tracking strategies: Chaperones capture iron in the cytosolic labile iron pool.Frontiers in molecular biosciences · 2023Review
- Percent Body Fat-Related Disparities of Serum Ferritin on the Risk of Lipid Metabolism Abnormalities in Children and Adolescents.International journal of environmental research and public health · 2022Article
- Iron metabolism in non-alcoholic fatty liver disease: A promising therapeutic target.Liver research (Beijing, China) · 2022Review
- Overexpression of Hepcidin Alleviates Steatohepatitis and Fibrosis in a Diet-induced Nonalcoholic Steatohepatitis.Journal of clinical and translational hepatology · 2022Article
- Another tool in the toolkit to manage iron overload.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- Mechanisms Underlying Antipsychotic-Induced NAFLD and Iron Dysregulation: A Multi-Omic Approach.Biomedicines · 2022Article
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-Alcoholic Fatty Liver Disease (NAFLD) is a common worldwide clinical and major public health problem affecting both adults and children in developed nations. Increased hepatic iron stores are observed in about one-third of adult NAFLD patients. Iron deposition may occur in parenchymal and/or non-parenchymal cells of the reticuloendothelial system (RES). Similar patterns of iron deposition have been associated with increased severity of other chronic liver diseases including HCV infection and dysmetabolic iron overload, suggesting there may be a common mechanism for hepatic iron deposition in these diseases. In NAFLD, iron may potentiate the onset and progression of disease by increasing oxidative stress and altering insulin signaling and lipid metabolism. The impact of iron in these processes may depend upon the sub-cellular location of iron deposition in hepatocytes or RES cells. Iron depletion therapy has shown efficacy at reducing serum aminotransferase levels and improving insulin sensitivity in subjects with NAFLD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.